Opinion|Videos|June 28, 2024
Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice
Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.
Advertisement
Episodes in this series
- The
MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice? - When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
2
From Stigma to Breakthrough: Psychedelic Medicine
3
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
4
How Pharmacy and Public Health Partner to Combat Infectious Diseases
5
